- Total operating expenses amounted to SEK 20.8 million, of which about 2/3 were clinical costs related to the Phase II studies in PMDD and menstrual migraine.
- The company conducted a directed share issue in October 2019, raising gross proceeds of SEK 47.5 million.
- On 31 December 2019, the company had a total cash position of SEK 130 million.
PREMENSTRUAL DYSPHORIC DISORDER
We enrolled the last patient in our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD), in September, and administered last injection on 26 January. We are on track to publish topline results by the end of April.
MENSTRUAL MIGRAINE TRIAL
We included the first patient in our Phase IIa proof-of-concept study in August and first patients started their treatment cycles in January. We expect last dose to be administered before the end of 2020, and topline results released Q1 2021.
In October we raised SEK 48 million, mainly for conducting a Phase IIa proof-of-concept study in this large orphan indication. We aim to initiate the study at the National Danish Tourette Center at the University hospital in Herlev before the end of 2020.
AUTOINJECTOR – YPSOMATE FROM YPSOMED
In October, we signed an agreement with the Swiss company Ypsomed for a customized Ypsomate autoinjector for Sepranolone proprietary to Asarina Pharma. It will be used from our first phase III PMDD study onwards.
Read the Full report HERE.